RNA Polymerase Inhibitor Enisamium for Treatment of Moderate COVID-19 Patients: A Randomized, Placebo-Controlled, Multicenter, Double-Blind Phase 3 Clinical Trial
Advances in Respiratory Medicine · 2024
DOI: 10.3390/arm92030021 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Advances in Respiratory Medicine, 2024. Verfasst von Olga Holubovska und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, O.O. Bogomolets National Medical University, T. Shevchenko Blvd. 13, 01601 Kyiv, Ukraine. Hauptthemen laut MEDLINE: COVID-19 Drug Treatment. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, joint Welcome Trust and Royal Society.
Abstract (Originalsprache)
Enisamium is an orally available therapeutic that inhibits influenza A virus and SARS-CoV-2 replication. We evaluated the clinical efficacy of enisamium treatment combined with standard care in adult, hospitalized patients with moderate COVID-19 requiring external oxygen. Hospitalized patients with laboratory-confirmed SARS-CoV-2 infection were randomly assigned to receive either enisamium (500 mg per dose, four times a day) or a placebo. The primary outcome was an improvement of at least two points on an eight-point severity rating (SR) scale within 29 days of randomization. We initially set out to study the effect of enisamium on patients with a baseline SR of 4 or 5. However, because the study was started early in the COVID-19 pandemic, and COVID-19 had been insufficiently studied at the start of our study, an interim analysis was performed alongside a conditional power analysis in order to ensure patient safety and assess whether the treatment was likely to be beneficial for one or both groups. Following this analysis, a beneficial effect was observed for patients with an SR of 4 only, i.e., patients with moderate COVID-19 requiring supplementary oxygen. The study was continued for these COVID-19 patients. Overall, a total of 592 patients were enrolled and randomized between May 2020 and March 2021. Patients with a baseline SR of 4 were divided into two groups: 142 (49.8%) were assigned to the enisamium group and 143 (50.2%) to the placebo group. An analysis of the population showed that if patients were treated within 4 days of the onset of COVID-19 symptoms (n = 33), the median time to improvement was 8 days for the enisamium group and 13 days for the placebo group (p = 0.005). For patients treated within 10 days of the onset of COVID-19 symptoms (n = 154), the median time to improvement was 10 days for the enisamium group and 12 days for the placebo group (p = 0.002). Our findings suggest that enisamium is safe to use with COVID-19 patients, and that the observed clinical benefit of enisamium is worth reporting and studying in detail.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, O.O. Bogomolets National Medical University, T. Shevchenko Blvd. 13, 01601 Kyiv, Ukraine.
- State Expert Center, Smolenska Str. 10, 03057 Kyiv, Ukraine.
- Department of Respiratory and Other Viral Infections, L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases of the NAMS of Ukraine, Amosova Str. 5a, 03083 Kyiv, Ukraine.
- Pharmalog Institut für Klinische Forschung GmbH, Oskar-Messter-Str. 29, 85737 Ismaning, Germany.
- Pharmaxi LLC, Filatova Str. 10A, 01042 Kyiv, Ukraine.
- Regenold GmbH, Zöllinplatz 4, 79410 Badenweiler, Germany.
ORCID-Profile: Alla Mironenko, Lutz Mueller
Förderung
- Wellcome Trust
- joint Welcome Trust and Royal Society
Zitieren
APA
Holubovska, O., Babich, P., Mironenko, A., Milde, J., Lebed, Y., Stammer, H., Mueller, L., Te Velthuis, A. J. W., Margitich, V., & Goy, A. (2024). RNA Polymerase Inhibitor Enisamium for Treatment of Moderate COVID-19 Patients: A Randomized, Placebo-Controlled, Multicenter, Double-Blind Phase 3 Clinical Trial. Advances in Respiratory Medicine. https://doi.org/10.3390/arm92030021
Vancouver
Holubovska O, Babich P, Mironenko A, Milde J, Lebed Y, Stammer H, et al. RNA Polymerase Inhibitor Enisamium for Treatment of Moderate COVID-19 Patients: A Randomized, Placebo-Controlled, Multicenter, Double-Blind Phase 3 Clinical Trial. Advances in Respiratory Medicine. 2024. doi:10.3390/arm92030021
BibTeX
@article{Holubovska2024,
author = {Holubovska, Olga and Babich, Pavlo and Mironenko, Alla and Milde, Jens and Lebed, Yuriy and Stammer, Holger and Mueller, Lutz and Te Velthuis, Aartjan J W and Margitich, Victor and Goy, Andrew},
title = {RNA Polymerase Inhibitor Enisamium for Treatment of Moderate COVID-19 Patients: A Randomized, Placebo-Controlled, Multicenter, Double-Blind Phase 3 Clinical Trial},
journal = {Advances in Respiratory Medicine},
year = {2024},
doi = {10.3390/arm92030021}
}
EUVIMED